Prevalence of Group C and in Patients With Sore Throat: A Meta-Analysis.

PURPOSE

The prevalence of Group C beta-hemolytic and among patients with sore throat in the outpatient setting has not been previously summarized. We set out to derive prevalence information from the existing literature.

METHODS

We performed a systematic review of MEDLINE for studies reporting the prevalence of or Group C or both in prospective, consecutive series of outpatients with sore throat, as well as laboratory-based studies of throat cultures submitted from primary care. We limited searches to studies where the majority of data was collected after January 1, 2000, to reflect contemporary microbiological methods and prevalences. Each author independently reviewed the articles for inclusion and abstraction of data; we resolved discrepancies by consensus discussion. We then performed a meta-analysis to calculate the pooled prevalence estimates using a random effects model of raw proportions.

RESULTS

A total of 16 studies met our inclusion criteria. The overall prevalences of Group C and were 6.1% (95% CI, 3.2%-9.0%) and 18.9% (95% CI, 10.5%-27.2%), respectively. When stratified by study type, the prevalences of Group C and in laboratory-based studies were 6.6% (95% CI, -1.0% to 14.2%) and 18.8% (95% CI, 6.5%-31.1%), respectively. In primary care patients with sore throat, Group C had a prevalence of 6.1% (95% CI, 3.1%-9.2%), while had a prevalence of 19.4% (95% CI, 14.7%-24.1%).

CONCLUSIONS

Group C and are commonly detected in patients with acute pharyngitis. Research is needed, however, to determine whether these bacteria are truly pathogenic in patients with pharyngitis and whether antibiotics reduce the duration of symptoms or the likelihood of complications.